Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2011 - 09 - 19

Press Release Menarini Group 19/09/2011

Due to health reasons, the President of Menarini I.F.R., Alberto Aleotti, has taken leave of his duties as head of the Menarini Group. His daughter, Lucia Aleotti (who will become the Group’s Vice President), and his son, Alberto Giovanni, announced the decision in a letter sent out this morning to all Company employees.

In the letter the Aleotti siblings trace the steps of their father’s outstanding entrepreneurial history in Menarini, highlighting how the total number of employees has increased from the original 180 to today’s 13,000 and how the Group’s territorial presence now covers more than 100 countries with a turnover exceeding 3 billion Euro.

The letter reads "It has been some months now since our father began to gradually pass on the decisional processes, even the strategic ones, to both us and the Group’s General Managers thus creating, with extraordinary intelligence, not a ‘One Man Company’ but a company capable of nurturing the talent of the men and women who work with us, a ‘school’ where one learns by example. A winning team."

"A team", the letter reassures, "which will continue to strengthen even further the philosophy based upon solid growth and development, far from ‘creative finance’ and speculation." A team which is able to not only face, but also successfully accomplish, all the new challenges that today’s market may place in front of a them – a company, the letter confirms, which will remain "totally independent".

The Menarini Group is the first Italian pharmaceutical company in the world, 15th in Europe out of 4,811 companies and 34th out of 14,051 companies world-wide (IMS World Review 2010, IMS World Review Pack 2010). The Group’s 2010 turnover was 3,031 million Euro and they currently employ 13,000 people all around the globe. The Menarini Group has always pursued two strategic objectives: Research and Internationalisation. The Group’s product range covers the most important therapeutic areas including: cardiovascular products, gastroenterological products, antibiotics and respiratory products, products for the treatment of diabetes, anti-inflammatory agents and analgesics. The Group has a strong presence throughout Europe and major countries in Asia, Africa, Central and South America. The Menarini Group provides products to patients in more than 100 countries.